Navigation Links
Skin 'sees' UV light, starts producing pigment
Date:11/3/2011

PROVIDENCE, R.I. [Brown University] For most people, tanning seems a simple proposition. A naturally light-skinned person lies in the sun for hours and ends up as bronzed as a Jersey Shore star. To scientists, the reaction of skin to ultraviolet light is more mysterious. A new study demonstrates that skin detects UVA radiation using a light-sensitive receptor previously found only in the eye and that this starts melanin production within a couple of hours. Until now, scientists only knew that melanin production occurred days after UVB radiation had already begun damaging DNA.

"As soon as you step out into the sun, your skin knows that it is exposed to UV radiation," said senior author Elena Oancea, assistant professor of biology in the Department of Molecular Pharmacology, Physiology, and Biotechnology at Brown University. "This is a very fast process, faster than anything that was known before."

Scientists believe that melanin protects the DNA in skin cells against damage from UVB rays by absorbing the incoming radiation. It isn't perfect, which is why people must use sun block. But the new study in the journal Current Biology shows that the body mounts its defense much sooner, well before it becomes apparent in the form of a tan.

In lab experiments with human melanin-producing skin cells called melanocytes, Oancea, graduate student Nadine Wicks, and their team discovered that the cells contain rhodopsin, a photosensitive receptor used by the eye to detect light. Moreover, they traced the steps of how rhodopsin unleashes calcium ion signals that instigate melanin production.

Eyes on the skin

In the team's first experiment, the scientists were looking to see whether UV light instigated a calcium signaling response. They found nothing. But guessing that the skin might sense light like the eyes do, they added retinal, a co-factor of opsin receptors including rhodopsin.

"When we did that, we saw an immediate and massive calcium response," said Wicks, the study's lead author.

Further investigations found that the cells contained rhodopsin RNA and protein. Under UV light, when the scientists reduced rhodopsin levels in the cells, calcium signaling was reduced. Later, when they starved cells of retinal, they found that melanin production dropped. The authors also determined that long-wavelength UVA light, rather than short-wavelength UVB light, is what stimulates rhodopsin in melanocytes.

During several experiments they were able to trace the following process: When UVA light strikes rhodopsin receptors with retinal, calcium signals are triggered within a few seconds. After an hour, measurable amounts of melanin accumulate, although in relatively small quantities compared to the production that will occur within 24 hours.

As much as they learned, Oancea and Wicks still have some questions. One is whether rhodopsin is acting alone or in concert with another yet undiscovered receptor. Another question is whether melanocytes immediately begin exporting melanin to other kinds of skin cells for protection or whether they keep the early supply for themselves.

Just because scientists are learning more about how the skin responds to and protects itself against UV radiation, Oancea said, that's no reason for people to change what they do to protect themselves.

"This doesn't say, 'Don't use sunscreen'," Oancea said.


'/>"/>

Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University
Source:Eurekalert

Related medicine news :

1. Packaging expert sees a social revolution in the evolving barcode
2. How Brain Sees the Big Picture May Affect Self-Image
3. Study Sees Link Between Psoriasis, Obesity in Kids
4. GOES-13 sees an extraordinarily early Atlantic low in the tropics
5. U.S. Sees Slowdown in Spending on Mental Health
6. GOES-13 Satellite sees Groundhogs Day on ice
7. United States Sees Record Drop in Teen Births From 2007-09
8. Study Sees Link Between Low Salt Levels, Fracture Risk in Older Adults
9. Study Sees Link Between Epilepsy, Infertility
10. Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation
11. Ear Infection is the Most Common Reason Why an American Child Sees the Doctor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... , ... August 18, 2017 , ... The Golseth Agency, ... the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide support ... In early June of this year, Christina and her children returned from out of ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... highly trained practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has ... imbalance and conditions of aging, such as menopause, andropause, thyroid disorder and adrenal ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage ... up its marketing efforts with its product now available through Jet.com. , After ... public. The effervescent powdered drink is designed to quickly detox the body thereby avoiding ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... numbers and call tracking and monitoring solutions, announced today the launch of a ... include a modern navigation and aesthetic, fully responsive design, and an enhanced search ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery about ... Winters. Diane is from Southwest Nebraska where she was raised on a farm. ... The story is fictional, but the friendships and mantra of ‘neighbors helping neighbors’ ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... -- Axium Pharmaceuticals Inc., the creator of the drug Truveta for ... of an IPO. The United States ... of a prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... staggering figure is the fact that Americans spent $42 billion on anxiety ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology: